Cambridge Cognition Holdings PLC Trading Update (3267O)

TIDMCOG

RNS Number : 3267O

Cambridge Cognition Holdings PLC

31 January 2023

31 January 2023

Cambridge Cognition Holdings plc

("Cambridge Cognition", the "Company" or the "Group")

Trading Update

Strong revenue growth with a complete solution for virtual CNS trials

Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce a trading update for the year ended 31 December 2022.

Unaudited highlights for the year ended 31 December 2022

-- Revenue ahead of market expectations: 25% growth in revenues to GBP12.6 million (2021: GBP10.1 million)

-- Increase in contracted order book to GBP17.6 million at 31 December 2022 (31 December 2021: GBP17.1 million), increasing to GBP20.1 million post-period end after acquisitions

-- Profit after tax for the year, before acquisition costs, of GBP0.2 million (2021: GBP0.5 million)

   --         Cash balance of GBP8.3 million at 31 December 2022 (31 December 2021: GBP6.8 million) 

The Company made significant progress, with strong organic revenue growth during 2022, and broadened the Company's platform and revenue opportunities further through the acquisition of eClinicalHealth Limited (trading as "Clinpal") in October 2022 and the acquisition of Winterlight Labs Inc ("Winterlight"), subsequent to the year end, in January 2023.

Revenue growth was ahead of market expectations at 25% in 2022 with earnings in line with market expectations. The acquisition of Clinpal did not contribute materially to trading results in 2022. Order intake for the year closed at GBP13.1 million, up 8% on the previous year's order intake of GBP12.1 million, excluding GBP3.6 million of large one-off orders taken in 2021. Order growth continued across the expanded product offering, driven in part by the continued demand for virtual clinical trials. The contracted order book remained healthy at the end of 2022 at GBP17.6 million (GBP17.1 million at 31 December 2021), together with a further GBP2.5 million added post year end with the acquisition of Winterlight, bringing the total contracted order book to GBP20.1 million. At least GBP9.5 million of the current contracted order book is expected to be recognised as revenue in 2023, subject to customer trial schedules. This gives approximately 60% visibility on market forecast revenues for 2023.

The market for virtual clinical trials for central nervous system ("CNS") disorders is large - larger than for any other therapeutic area - with around 250 being started every year(1) . The acquisition of Clinpal in October 2022 has strengthened the Company's position in this rapidly growing market, combining its CNS expertise with Clinpal's end-to-end virtual capability. From this strengthened position, the Company has continued to grow its total addressable market with the acquisition of Winterlight and its voice technology in January 2023. The market for voice biomarkers for all conditions is reported to be growing at 66% per annum and, starting from a modest base, is predicted to be around US$220 million by 2026(2) .

With Cambridge Cognition's gold-standard cognitive assessments, Winterlight's leading vocal biomarker technology, and Clinpal's end-to-end virtual platform, the combined Company is well positioned for further considerable growth.

The Company expects to announce its results in April 2023.

The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.

References.

1. GlobalData. Virtual trials run by pharma by therapeutic area Jan 2021 - Aug 2022

2. Coherent Market Insights, 2019

Enquiries:

 
 Cambridge Cognition Holdings Plc               Tel: [phone] 
  Matthew Stork, Chief Executive Officer         [e-mail] 
  Stephen Symonds, Chief Financial Officer 
 Panmure Gordon (UK) Limited (NOMAD and Joint   Tel: [phone] 
  Broker)                                        (Corporate Finance) 
  Freddy Crossley / Emma Earl                    (Corporate Broking) 
  Rupert Dearden 
 Dowgate Capital Limited (Joint Broker)         Tel: [phone] 
  David Poutney / James Serjeant 
 IFC Advisory Ltd (Financial PR and IR)         Tel: [phone] 
  Tim Metcalfe / Graham Herring / Zach Cohen     [e-mail] 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TSTSDEESSEDSELF

(END) Dow Jones Newswires

January 31, 2023 02:00 ET (07:00 GMT)